Article 1:
Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis
Clinical Gastroenterology and Hepatology 2022;20:136–144
DOI: https://doi.org/10.1016/j.cgh.2020.09.043
PDF: Article
Summary: Irritable bowel syndrome (IBS) is one of the most expensive gastroenterological conditions and is an ideal target for developing a value-based care model. We assessed the comparative cost benefit of treatments for IBS with diarrhea (IBS-D), the most common IBS subtype from insurer and patient perspectives. We constructed a decision analytic model assessing trade-offs among guideline-recommended and recently FDA-approved drugs, supplements, low FODMAP diet, cognitive behavioral therapy (CBT). Outcomes and costs were derived from systematic reviews of clinical trials and national databases. Health-gains were represented using quality-adjusted life years (QALY).
Presenter: Jeremy Gillespie
Additional Resources:
Article 2:
MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
Gastroenterology 2021;161:1887–1895
DOI: https://doi.org/10.1053/j.gastro.2021.08.050
PDF: Article
Summary: The Model for End-Stage Liver Disease(MELD) has been established as a reliable indicator of short term survival in patients with end-stage liver disease. The current version (MELDNa), consisting of the international normalized ratio and serum bilirubin, creatinine, and sodium, has been used to determine organ allocation priorities for liver transplantation in the United States. The objective was to optimize MELD further by taking into account additional variables and updating coefficients with contemporary data.
Presenter: Jackie Henson
Additional Resources:
